Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
James L Gulley, Michael Borre, Nicholas J Vogelzang...
https://pubmed.ncbi.nlm.nih.gov/30817251/Actively Recruiting
Led by West China Hospital · Updated on 2026-03-17
12
Participants Needed
1
Research Sites
69 weeks
Total Duration
Researchers are evaluating an engineered mitochondrial vaccine in patients with advanced solid tumors to assess its safety, tolerability, and early signs of therapeutic effect. This phase 1, dose-escalation clinical trial aims to address the urgent need for new treatments in advanced malignant solid tumors, which currently have limited options and poor outcomes. The study leverages mitochondria engineered to express tumor-specific antigens to activate the immune system against cancer cells. Participants are assigned to one of four dose groups 25, 50, 100, or 200 micrograms per dose and receive subcutaneous injections of the vaccine following a prime-boost schedule. This regimen includes three primary immunization doses, one booster dose, and personalized treatment afterward. The study carefully monitors escalating doses to evaluate safety and preliminary anti-tumor activity. During the trial, participants undergo regular assessments including monitoring for adverse events over one year, and evaluation of tumor response, disease control, progression-free survival, and overall survival up to six months to one year. Various laboratory tests and physical examinations ensure organ function and overall health throughout the study. The total participation duration depends on individual response and follow-up schedules, with close safety monitoring provided by the researchers.
CONDITIONS
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
X
Xingchen Peng, Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
West China Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of the prime-boost schedule plus personalized treatment as determined by the trial protocol
Participants receive the engineered mitochondrial vaccine through a prime-boost schedule consisting of 3 doses of primary immunization, 1 dose of boost immunization, followed by personalized treatment.
4 vaccination visits and additional follow-up visits as scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
James L Gulley, Michael Borre, Nicholas J Vogelzang...
https://pubmed.ncbi.nlm.nih.gov/30817251/Stefano Pierini, Chongyun Fang, Stavros Rafail...
https://pubmed.ncbi.nlm.nih.gov/26378078/Sze-Wah Tse, Kristine McKinney, William Walker...
https://pubmed.ncbi.nlm.nih.gov/33677092/Jingwen Luo, Fei Mo, Zhe Zhang...
https://pubmed.ncbi.nlm.nih.gov/39164536/Lu Fan, Dingfeng Wu, Vadim Goremykin...
https://pubmed.ncbi.nlm.nih.gov/32661403/Chunju Fang, Fei Mo, Li Liu...
https://pubmed.ncbi.nlm.nih.gov/32398808/West China Hospital
Lead Sponsor